Drug intelligence / Profile preview

YDC104

Development stage: Preclinical
Lead developer: YD Global Life Science

Overview

YDC104 is an early-stage pharmaceutical candidate being developed for the treatment of Alzheimer's disease. It is part of the pipeline of YD Global Life Science and is being co-developed in collaboration with SapiensBio and the Alzheimer's Disease Data Initiative (ADDI) at the University of Cambridge. As of the latest reports, the drug is in the 'Hit' stage of preclinical development. While the specific biological target and therapeutic modality are currently held as confidential, the program represents a collaborative effort to identify novel therapeutic interventions for neurodegenerative pathology.

Beyond the preview

Go deeper on YDC104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YDC104.

Explore the full profile